Shots:
- The US FDA has approved label expansion of Bravecto Quantum (Fluralaner for Extended-Release Injectable Suspension) for dogs to treat & control Asian longhorned tick (H. longicornis) & Gulf Coast tick (A. maculatum) for 12mos.
- The extended-release injectable Bravecto Quantum provides a once-yearly dosing option for improved compliance & continuous protection, & is available exclusively through licensed veterinarians
- Bravecto Quantum was previously approved in the US on July 10, 2025, for killing adult fleas & preventing infestations, & for control of ticks (Ixodes scapularis, Dermacentor variabilis, Rhipicephalus sanguineus for 12mos.; A. americanum for 8mos.) in dogs (≥6mos.)
Ref: Businesswire | Image: Merck Animal Health | Press Release
Related News: Merck Animal Health’s Numelvi Secures the FDA Approval for Control of Pruritus Associated with Allergic Dermatitis in Dogs
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
